Monoclonal gammopathy of undetermined significance: A primary care guide | Zendy

Jack Khouri | Zendy; Christy Samaras | Zendy; Jason Valent | Zendy; Alex Mejia Garcia | Zendy; Beth Faiman | Zendy; Saveta Mathur | Zendy; Kim Hamilton | Zendy; Megan O. Nakashima | Zendy; Matt Kalaycio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Monoclonal gammopathy of undetermined significance: A primary care guide

Author(s) -

Jack Khouri,

Christy Samaras,

Jason Valent,

Alex Mejia Garcia,

Beth Faiman,

Saveta Mathur,

Kim Hamilton,

Megan O. Nakashima,

Matt Kalaycio

Publication year - 2019

Publication title -

cleveland clinic journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.359

H-Index - 63

eISSN - 1939-2869

pISSN - 0891-1150

DOI - 10.3949/ccjm.86a.17133

Subject(s) - medicine , monoclonal gammopathy of undetermined significance , monoclonal gammopathy , multiple myeloma , lymphoproliferative disorders , monoclonal , monoclonal antibody , immunology , lymphoma , antibody

Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research